GlobalData on MSN3d
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) ...
Hosted on MSN4h
Tezepelumab for Severe Asthma Improves the Odds of a Good Night's Sleep
Patients with severe, uncontrolled asthma had significantly higher odds of improvement in asthma-related sleep disturbances ...
pulmonologyadvisor12h
Rescue Med Combo Benefits Patients With Intermittent or Mild Persistent Asthma
Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.
FiercePharma4d
AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'
In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...
Immune therapy shows promise for asthma, heart disease—and even ageing
Two years later, she became the first paediatric patient to be offered a form of treatment called CAR-T, in which the body’s ...
copdnewstoday4d
Low climate-impact inhalers as effective as pressurized ones: Study
Low climate-impact corticosteroid inhalers are as effective as high climate impact inhalers for COPD and asthma outcomes, per ...
Nursing in Practice2d
Quick quiz: Switching patients onto ‘greener’ inhalers
Our Nursing in Practice quick quizzes aim to test your knowledge through a series of illustrative cases and scenarios. Work ...
Data from new national study exposes oral corticosteroids overuse in Canadian patients with severe asthma
The data from the real-world evidence study "Characterizing uncontrolled severe asthma in Canada (ALERT)" was recently ...
infectiousdiseaseadvisor.com3d
Switching Between Inhalers, Both pMDI and DPI, Common in Asthma, COPD
Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.
Peak asthma season means more inhaler puffs, and more emissions
Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...
EuropaWire4d
Early Success: AstraZeneca’s Airsupra Proves Highly Effective in Reducing Severe Asthma Risks in Phase III Trial
AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...
Asthma Treatment Market Size Expected to Reach USD 35.93 Bn by 2034
The global asthma treatment market size was valued at USD 27.51 billion in 2023 and is expected to reach around USD 35.93 billion by 2034. It is growing at a CAGR of 2.42% from 2024 and 2034. The ...